Advertisement

Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon

Published:September 01, 2006DOI:https://doi.org/10.1016/j.jhep.2006.08.007
      This report concerns a patient with chronic hepatitis C in whom the lack of response to pegylated interferons (PEG-IFN) seems due to the presence of neutralizing antibodies (Nab) to IFN during treatment. The patient’s condition was also aggravated by myasthenia gravis (MG) appearing during re-treatment with natural leukocyte interferon alpha (nIFNα).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Antonelli G.
        • Giannelli G.
        • Currenti M.
        • Simeoni E.
        • Milella M.
        • et al.
        Fate of antibody to interferon (IFN) in chronic hepatitis C patients treated with recombinant IFN alpha2 retreated with lymphoblastoid IFN alpha.
        Int Hepatol Commun. 1995; 4: 232-237
        • Grossberg S.E.
        • Kawade Y.
        • Kohase M.
        • Yokoyama H.
        • Finter N.
        The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems.
        J Interferon Cytokine Res. 2001; 21: 729-742
        • Antonelli G.
        • Currenti M.
        • Turriziani O.
        • Dianzani F.
        Neutralizing antibodies to Interferon-α: relative frequency in patients treated with different interferon preparations.
        J Infect Dis. 1991; 163: 882-885
        • Van der Eijk A.A.
        • Vrolijk J.M.
        • Haagmans B.L.
        Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C.
        NEJM. 2006; 354: 1323-1324
        • Berg T.
        • Hopf U.
        • Schuff-Werner P.
        Sustained remission of chronic hepatitis C after a change to human leukocyte interferon-alpha in a difficult-to-treat patient with breakthrough phenomenon associated with antibodies against recombinant interferon-alpha.
        AJG. 2001; 96: 612-614
        • Milella M.
        • Antonelli G.
        • Santantonio T.
        • Giannelli G.
        • Currenti M.
        • Monno L.
        • et al.
        Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN.
        Hepato-Gastroenterology. 1995; 42: 201-204
        • Milella M.
        • Antonelli G.
        • Santantonio T.
        • Currenti M.
        • Monno L.
        • Mariano N.
        • et al.
        Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection.
        Liver. 1993; 13: 146-150
        • Roffi L.
        • Mels G.C.
        • Antonelli G.
        • Bellati G.
        • Panizzuti F.
        • Piperno A.
        • et al.
        Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management.
        Hepatology. 1995; 21: 645-649
        • Reading P.J.
        • Newman P.K.
        Untreated hepatitis C may provoke myasthenia gravis.
        J Neurol Neurosurg Psychiatry. 1998; 64: 820
        • Eddy S.
        • Wim R.
        • Peter V.E.
        • Tanja R.
        • Jan T.
        • Werner V.S.
        Myasthenia gravis: another autoimmune disease associated with hepatitis C virus infection.
        Dig Dis Sci. 1999; 44: 186-189
        • Weegink C.J.
        • Robert A.F.M.
        • Chamuleau R.A.
        • Reesink H.W.
        • Molenaar D.S.
        Development of myasthenia gravis during treatment of chronic hepatitis C with interferon and ribavirin.
        J Gastroenterol. 2001; 36: 723-724
        • Dionisiotis J.
        • Zoukos Y.
        • Thomaides T.
        Development of myasthenia gravis in two patients with multiple sclerosis following interferon β treatment.
        J Neurol Neurosurg Psychiatry. 2004; 75: 1079